welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Lilly And Precision BioSciences Announce Genome Editing Research Collaboration And License Agreement
Clinical Trials and Research

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

Eli Lilly and Company and Precision BioSciences, Inc. announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

Genome editing technologies enable precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. ARCUS is a unique, proprietary, and versatile genome editing platform with attributes including specificity, ability to make a variety of efficient edits (knock-in, knock-out, and repair), and small size, thereby enabling a range of therapeutic editing. The platform is derived from a natural genome-editing enzyme called I-CreI, a homing endonuclease that can be optimized to control for potency and specificity.

Nov 20, 2020
CURE DUCHENNE VENTURES ANNOUNCES FUNDING OF MESENTECH, INC. WITHIN A FUNDING COLLABORATION WITH THE CHARLES H. HOOD FOUNDATION
Business

CURE DUCHENNE VENTURES ANNOUNCES FUNDING OF MESENTECH, INC. WITHIN A FUNDING COLLABORATION WITH THE CHARLES H. HOOD FOUNDATION

CURE DUCHENNE VENTURES INVESTMENT SUPPORTS THE DEVELOPMENT OF A NEW THERAPY FOR BONE WASTAGE IN DUCHENNE MUSCULAR DYSTROPHY 

Newport Beach, CA (November 10, 2020) – CureDuchenne Ventures, the research funding arm of CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), announced an investment in Mesentech Inc., a regenerative medicine company with a prodrug platform that selectively delivers therapeutics to bone.  The investment is part of a new joint funding collaboration with the Charles H. Hood Foundation (CHF) that looks to advance early-stage research for pediatric conditions. 

Nov 10, 2020